WAIVER August 11, 2020August 11, 2020 • August 14th, 2020 • Novartis Pharma Ag • Biological products, (no disgnostic substances) • Delaware
THIS WAIVER (this “Waiver”) is made with reference to the License and Collaboration Agreement dated September 25, 2018 (the “License Agreement”) by and among Novartis Pharma AG, a company (Aktiengesellschaft) organized and existing under the laws of Switzerland (“Novartis”), Cellular Biomedicine Group, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), and certain of the Company’s subsidiaries as parties thereto (such subsidiaries and the Company collectively, “CBMG”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. This Waiver is given by Novartis on the date set forth above (the “Waiver Effective Date”) in connection with the Merger (defined below).
WAIVER August 11, 2020August 11, 2020 • August 14th, 2020 • Novartis Pharma Ag • Biological products, (no disgnostic substances) • Delaware
THIS WAIVER (this “Waiver”) is made with reference to the Toll Manufacturing and Supply Agreement dated December 21, 2018 (the “Supply Agreement”) by and among Novartis Pharma AG, a company (Aktiengesellschaft) organized and existing under the laws of Switzerland (“Novartis AG”), Beijing Novartis Pharma Co., Ltd., a company organized and existing under the laws of the People’s Republic of China (“Novartis China” together with Novartis AG, “Novartis”), Cellular Biomedicine Group, Inc., a corporation organized and existing under the laws of Delaware, (the “Company”), and Shanghai Cellular Biopharmaceutical Group Ltd., a company organized and existing under the laws of the People’s Republic of China (“CBMG China”, together with the Company, “CBMG”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Supply Agreement. This Waiver is given by Novartis on the date set forth above (the “Waiver Effective Date”) in connection with the Merger (defined b
